Qiagen (QGEN) Agrees to €10.8 Billion Acquisition by EQT at a 40
Qiagen (QGEN) agreed to a €10.8 billion all-cash acquisition by EQT at €46.50 per share, a 40.3% premium over its July 2026 closing price. The deal, approved by Qiagen's board, is expected to close by mid-2027. Qiagen's GF Value™ is $50.02, indicating fair valuation, with a GF Score™ of 77 out of 100. The company's P/E ratio is 25.39x, near its 5-year median of 26.76x.
How this was made
The 30-second read
Why it matters
The acquisition price represents a 40.3% premium, implying immediate upside for shareholders, but closing depends on regulatory approval by mid‑2027.
Market read
First‑report of a major M&A transaction in the biotech space; likely to move QGEN stock and influence sector sentiment.
What to watch
Integration risk and potential debt load on EQT may affect long‑term value.
Background
Qiagen (NYSE: QGEN) is a Netherlands‑based molecular diagnostics company; EQT is a global private‑equity firm.
Ticker impact
Qiagen announced a definitive all‑cash acquisition by EQT at €46.50 per share, a 40.3% premium to its July price.
likely upward pressure as investors price in the acquisition premium
A 40% premium on a mid‑cap biotech is material; the market typically bids up the target stock ahead of closing.
Market effects
Consolidation in molecular diagnostics may spur M&A activity among peers.
European private‑equity interest in U.S. biotech could attract more cross‑border capital.
Large‑cap PE deal signals confidence in healthcare sector growth.
Counterpoint
Deal could face regulatory hurdles; if blocked, QGEN may fall back to pre‑deal levels.
Key entities
- CompanyQiagen NV
Target biotech firm being acquired.
- Private‑Equity FirmEQT
Acquirer offering €10.8 billion in cash.
